Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Revenue
Below are the diagnostic substances stocks on the NASDAQ in terms of revenue.
The trailing-twelve-month revenue at IDEXX Laboratories (NASDAQ: IDXX) is $1.34 billion. IDEXX's PEG ratio is 2.10.
The trailing-twelve-month revenue at Neogen (NASDAQ: NEOG) is $216.35 million. Neogen's ROE for the same period is 11.22%.
The trailing-twelve-month revenue at Abaxis (NASDAQ: ABAX) is $188.77 million. Abaxis's operating margin for the same period is 14.31%.
The trailing-twelve-month revenue at Meridian Bioscience (NASDAQ: VIVO) is $188.69 million. Meridian Bioscience had $40.36 million in total cash for the latest quarter.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Diagnostic Substances Industry NASDAQ revenueTrading Ideas